Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 4, Issue 12, Pages 1499-1506Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425250802531767
Keywords
accelerator mass spectrometry; drug development; microdosing; pharmacokinetic linearity
Ask authors/readers for more resources
Background: Microdosing studies (human Phase 0) are used to select drug candidates for Phase I clinical trials on the basis of their pharmacokinetic properties, using subpharmacologic doses (maximum 100 mu g). There are questions as to whether pharmacokinetic data obtained at these low doses will predict those at the clinically relevant dose. Objective: To review the current literature on microdosing and assess how well microdose data have predicted the pharmacokinetics obtained at a therapeutic dose. Methods: All data published in the peer reviewed literature comparing pharmacokinetics at a microdose with a therapeutic dose were reviewed, excluding those studies aimed at imaging. Conclusions: Of the 18 drugs reported, 15 demonstrated linear pharmacokinetics within a factor of 2 between a microdose and a therapeutic dose. Therefore, data that support the utility of microdosing are beginning to emerge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available